Medical Condition News

RSS

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

IRSF announces funding of new clinical study with disease-modifying therapy treatment for Rett syndrome

Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients.

22 Sep 2009

Major shift in cancer research priorities needed

Cancer research is too focused on new drug development, while not enough money and effort is being devoted to pursuing important advances in knowledge likely to have the biggest impact on combating the disease in the next few decades, a leading research policy expert says, adding that a major shift in research priorities will be crucial to the ability to cope with the coming wave of cancer cases.

22 Sep 2009

Drug-eluting stents effective for diabetic patients

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Diabetes more prevalent in African Americans due to living conditions

The higher incidence of diabetes among African Americans when compared to whites may have more to do with living conditions than genetics, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. The study, available online in advance of publication in the October 2009 edition of the Journal of General Internal Medicine, found that when African Americans and whites live in similar environments and have similar incomes, their diabetes rates are similar, which contrasts with the fact that nationally diabetes is more prevalent among African Americans than whites.

22 Sep 2009

Survey: 77% of Latino women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 77 percent of Latinas reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 63 percent of Latinas who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 14 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

35 million people around the world affected by Alzheimer's disease: Nancy Pelosi

"Alzheimer's disease is a scourge afflicting Americans in every state and community. According to a new report, it affects 35 million people around the world -- and that number is expected to nearly double in 20 years, to more than 65 million in 2030.

22 Sep 2009

Poor money management: A sign of developing Alzheimer's disease

New research finds poor money management skills may indicate that a person with mild memory problems will soon develop Alzheimer's disease. The study is published in the September 22, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Moses Cone Health System installs TomoTherapy cancer treatment system

TomoTherapy Incorporated announced today that Moses Cone Health System has installed North Carolina's first TomoTherapy® cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C.

22 Sep 2009

Survey: 78% of African American women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 78 percent of African American women reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 48 percent of African American women who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 16 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

MRS could be effective for identifying diabetes

Researchers have long suspected that overweight people tend to have large fat deposits in their pancreases, but they've been unable to confirm or calculate how much fat resides there because of the organ's location.

22 Sep 2009

Study on mice reveals that short term stress can prevent cancer

Researchers at the Stanford University School of Medicine have shown that, at least in laboratory mice, bouts of relatively short-term stress can boost the immune system and protect against one type of cancer. Furthermore, the beneficial effects of this occasional angst seem to last for weeks after the stressful situation has ended. The finding is surprising because chronic stress has the opposite effect -- taxing the immune system and increasing susceptibility to disease.

22 Sep 2009

Edwards Lifesciences updates on its SAPIEN valve clinical programs

Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced new clinical data demonstrating 100 percent freedom from structural deterioration of the Edwards SAPIEN valve at 18 months, as well as positive midterm patient outcomes resulting from the application of learnings from earlier clinical programs.

22 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

Osteoporosis a growing concern in Asia

A new audit report issued by the International Osteoporosis Foundation (IOF) today shows that osteoporosis is a serious and growing problem throughout Asia.

22 Sep 2009

Bipolar disorder patients impaired in work, family and social life

In a review by a group of Spanish investigators in the current issue of Psychotherapy and Psychosomatics what happens in terms of functioning and disability to patients with bipolar disorder is described.

22 Sep 2009

HearAtLast Holdings opens new tinnitus clinic in Canada

(PINKSHEETS: HRAL) HearAtLast Holdings, Inc., a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced today that the Company is in the final development stage of a new Tinnitus Clinic located in the prominent Kingsway Community of Toronto, Ontario Canada.

22 Sep 2009

Researcher can anticipate immune response in Alzheimer's patients

A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

22 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009